Compare Cassava Sciences Inc (FLNA) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Intuitive Surgical, Inc. — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Intuitive Surgical, Inc. trades at $400.18 (market cap $137.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 2592.4× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | ISRG | |
|---|---|---|
Market Cap | $53.14M | $137.76B |
Sector | Health | Health |
52-Week High | $4.64 | $592.85 |
52-Week Low | $1.09 | $379.50 |
Enterprise Value | -$33.43M | $133.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Intuitive Surgical (ISRG) trades at $379.50, down 6.78% amid broader market pressure, yet maintains strong fundamentals with 28.15% net margins and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but shows oversold RSI conditions. Recent news highlights competitive pressures but also strong da Vinci 5 adoption and upcoming Q2 earnings on July 16, where analysts expect another beat. Revenue growth remains robust at $10.06B for 2025, up from $8.4B in 2024.
Despite near-term volatility, ISRG's leadership in robotic surgery and analyst consensus price target of $552.36 suggest significant upside. Key risks include intensifying global competition and margin pressures, but the company's innovation pipeline and expanding procedure volumes support long-term growth. Institutional sentiment remains positive with 69.6% buy ratings, positioning ISRG as a compelling recovery candidate post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
